Venous thromboembolism risk with JAK inhibitors: A Meta‐analysis

Review of 42 studies found no increased risk, with incidence rates for VTE, PE & DVT with JAK inhibitor use of 0.68 (95%CI 0.36-1.29), 0.44 (0.28-0.70) and 0.59 (0.31-1.15) respectively. Authors state data do not support current warnings around VTE risk for JAK inhibitors.

SPS commentary:

SPCs for JAK inhibitors (baricitinib, upadacitnib and tofacitinib) currently advise that DVTs and PEs have been reported in patients receiving JAK inhibitors, and that they should be used with caution in patients at high risk for DVT/PE.

Arthritis & Rheumatology